Back to Search
Start Over
EGAR, A Food Protein-Derived Tetrapeptide, Reduces Seizure Activity in Pentylenetetrazole-Induced Epilepsy Models Through α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionate Receptors.
- Source :
-
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2017 Jan; Vol. 14 (1), pp. 212-226. - Publication Year :
- 2017
-
Abstract
- A primary pathogeny of epilepsy is excessive activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors (AMPARs). To find potential molecules to inhibit AMPARs, high-throughput screening was performed in a library of tetrapeptides in silico. Computational results suggest that some tetrapeptides bind stably to the AMPAR. We aligned these sequences of tetrapeptide candidates with those from in vitro digestion of the trout skin protein. Among salmon-derived products, Glu-Gly-Ala-Arg (EGAR) showed a high biological affinity toward AMPAR when tested in silico. Accordingly, natural EGAR was hypothesized to have anticonvulsant activity, and in vitro experiments showed that EGAR selectively inhibited AMPAR-mediated synaptic transmission without affecting the electrophysiological properties of hippocampal pyramidal neurons. In addition, EGAR reduced neuronal spiking in an in vitro seizure model. Moreover, the ability of EGAR to reduce seizures was evaluated in a rodent epilepsy model. Briefer and less severe seizures versus controls were shown after mice were treated with EGAR. In conclusion, the promising experimental results suggest that EGAR inhibitor against AMPARs may be a target for antiepilepsy pharmaceuticals. Epilepsy is a common brain disorder characterized by the occurrence of recurring, unprovoked seizures. Twenty to 30 % of persons with epilepsy do not achieve adequate seizure control with any drug. Here we provide a possibility in which a natural and edible tetrapeptide, EGAR, can act as an antiepileptic agent. We have combined computation with in vitro experiments to show how EGAR modulates epilepsy. We also used an animal model of epilepsy to prove that EGAR can inhibit seizures in vivo. This study suggests EGAR as a potential pharmaceutical for the treatment of epilepsy.<br />Competing Interests: Compliance with Ethical Standards Funding and disclosure This work was supported by Science and Technology Planning Project of Guangdong Province (2013B010404011). The authors declare no conflict of interest.
- Subjects :
- Animals
Anticonvulsants isolation & purification
Anticonvulsants pharmacology
CA1 Region, Hippocampal physiopathology
Cells, Cultured
Disease Models, Animal
Epilepsy chemically induced
Epilepsy physiopathology
Excitatory Postsynaptic Potentials drug effects
Fish Proteins isolation & purification
Fish Proteins pharmacology
High-Throughput Screening Assays
Mice
Mice, Inbred C57BL
Models, Molecular
Neurons drug effects
Neurons physiology
Pentylenetetrazole
Protein Structure, Tertiary
Salmon
Seizures chemically induced
Seizures physiopathology
Skin chemistry
Anticonvulsants administration & dosage
CA1 Region, Hippocampal drug effects
Epilepsy prevention & control
Fish Proteins administration & dosage
Receptors, AMPA antagonists & inhibitors
Seizures prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1878-7479
- Volume :
- 14
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 27783277
- Full Text :
- https://doi.org/10.1007/s13311-016-0489-4